Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
DURHAM, N.C., Jan. 24, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Chief Executive Officer, will present at the NobleCon13 – Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida on Tuesday, January 31, 2017, at 10 a.m. Eastern Standard Time.
The link to the live audio webcast and replay of the presentation may be accessed on Heat’s corporate website at http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami. The Zolovax patent portfolio also includes gp96 vaccines targeting West Nile virus, Dengue and yellow fever among others.
For more information, please visit www.heatbio.com.
Contact: Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
